PSIL-006 is a next-generation, psilocybin derivative with broad applicability and a patient-friendly profile. Because of its non-hallucinogenic profile, PSIL-006 is designed to be a good candidate for take-home use and insurability.
Preclinical Data Shows:
- PSIL-006 has demonstrated no treatment-limiting side effects, such as hallucinations.
- Animal model testing demonstrated efficacy with a single dose.
- PSIL-006 has demonstrated a positive effect on serotonin receptor 2A (5-HT2A) which is commonly targeted in the brain for the rapid treatment of psychiatric conditions.
